The CEO of German pharmaceutical company BioNTech has said he remains confident the company’s Covid vaccine, developed in partnership with Pfizer, will be effective against the highly-infectious variants of the virus discovered in the U.K. and South Africa.
“We are confident that based on the mechanism of our vaccine, even though there are mutations, we believe that the immune response which is induced by our vaccine could also deal with (a) mutated virus,” Dr. Ugur Sahin, co-founder and CEO of BioNTech, told CNBC’s Meg Tirrell on Monday.